Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.80 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.79 |
| ▸ | TYMP | P19971 | 2/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14669196 | 1.00 | FGFR1 (0.80) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL14669220 | 1.00 | FGFR1 (0.80) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL16574525 | 0.92 | FGFR1 (0.68) | FGFR1SLC22A6TYMPHPRT1 | |
| SCHEMBL14665357 | 0.91 | FGFR1 (0.67) | FGFR1SLC22A6TYMPHPRT1 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 0.89 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL3948 | 0.89 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.89 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL1389452 | 0.89 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL14665385 | 0.89 | FGFR1 (0.66) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946561 | 0.88 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | FGFR1 3477/4885SLC22A6 2075/4885TYMP 6/4885 |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | FGFR1 3477/4885SLC22A6 2075/4885TYMP 6/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | FGFR1 3477/4885SLC22A6 2075/4885TYMP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.